Alex Hillenbrand

Here are 7 of the biggest nephrology stories from Q2 of 2026!

Catch up on the nephrology headlines you missed in June 2026.

Abivax’s ABTECT Part 2 showed Week 44 responses and safety consistency with obefazimod in refractory UC patients.

FDA sends fresh CRL for Unicycive’s OLC; manufacturing inspection delays approval, while data support a lower pill-burden phosphate binder.

Tulisokibart became the first anti-TL1A therapy to achieve clinical remission in a phase 3 ulcerative colitis trial.

Baseline characteristics, including sex and comorbidities, were associated with semaglutide weight loss outcomes in >36,000 adults.

Fezolinetant's CNS safety Profile Reassures Across More Than 3,000 Women in Pooled Phase 3 Analysis at ENDO 2026

ENDO 2026 data suggest tirzepatide may improve renal transplant eligibility in patients with T2D, CKD, and severe obesity.

At ENDO 2026, findings suggest SBP reductions in adults with diabetes are driven by weight loss, not GLP-1 therapy type.

Greater BMI reduction with semaglutide in adolescents with severe obesity was tied to improved triglycerides, TG/HDL ratio, and HbA1c

New systematic review of 7012 kidney transplant recipients with T2D finds GLP-1 receptor agonists cut major adverse kidney events and mortality by 61%.

MiniMed 780G improved HbA1c and time in range in real-world diabetes data presented at ENDO 2026, with minimal hypoglycemia risk.

Learn what the first-ever CKM syndrome guideline means for screening, treatment, and the connection between heart disease, kidney disease, diabetes, and obesity.

Catch up on the key nephrology news, research findings, and expert insights featured on HCPLive throughout May 2026.

FDA accepts the BLA for povetacicept in IgA nephropathy, supported by positive phase 3 RAINIER trial data.

Catch up on 5 notable studies and trial updates from DDW 2026!

Catch up on the hematology news and data you missed from April 2026.

COBRA findings suggest 1 day of antibiotic treatment is preferred in acute cholangitis after adequate biliary drainage compared to longer guidelines.

Catch up on 5 nephrology headlines you missed in April 2026, including WCN coverage, FDA updates, and trial data.

Ravulizumab reduced proteinuria by week 10 and met the primary endpoint in the phase 3 I CAN trial in IgA nephropathy.

Etavopivat reduced VOC events by 27% and improved hemoglobin response in the phase 3 HIBISCUS trial in sickle cell disease.

FDA fully approves sparsentan for FSGS, offering the first oral non-immunosuppressive option that targets podocyte injury and cuts proteinuria.

Catch up on nephrology headlines you missed from Q1 2026.

HCPLive’s editorial team has compiled 5 of the most informative discussions, along with key data from the WCN.

2-year results from phase 3 APPLAUSE-IgAN demonstrate slower eGFR decline, reduced composite kidney failure, and proteinuria in IgAN patients treated with iptacopan.

Catch up on the guideline updates, trial news, and featured content from March 2026.

ASH publishes 33 clinical recommendations and 4 good practice statements for the diagnosis and treatment of severe and very severe acquired aplastic anemia.

ACG's 24 new HE recommendations tackle ammonia testing, lactulose titration, protein intake, and transplant criteria for cirrhosis patients.